Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX ...

Privately-held Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of ...

Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Read more ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

KRBL Ltd has revamped the packaging of its 'India Gate' basmati rice brand after 25 years. The company aims to increase its market share from 42 per cent to 60 per cent within 3-5 years by targeting ...

LONDON, GREATER LONDON, UNITED KINGDOM, January 31, 2025 /EINPresswire / -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

In Stallergenes Greer, Palforzia has an owner with a dedicated focus on diagnosing and treating allergies, with its own range of products used ... off dermatology brand Galderma, which it bought ...

The time is ripe for such innovation: between October 2019 and May 2022, there was a 950% increase in the use of unique digital endpoints in industry-sponsored trials of new medical products ...

DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products ...